Tag Archives: biotechnology news

Myriad vs. Mayo – Detection vs. Processing at the Fed. Cir.

Rapid Litigation Mgmt v. CellzDirect: Splitting Detection of a Natural Phenomenon from its Application to Yield a Product. Courtenay G. Brinkerhoff at pharmapatentsblog.com summarized the oral arguments at the Fed. Cir. (App. No. 15-1570) conducted on April 5, 2016 in … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 1 Comment

Ohio Willow Wood’s Appeal of IC Finding Goes Up In Smoke

On February 19th, the Fed. Cir. affirmed a District Court’s finding of inequitable conduct in Ohio Willow Wood Co. (OWW) v. Alps South (Alps), LLC, following the Fed. Cir.’s remand of summary judgment of no inequitable conduct in 2013. (Ohio … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Therasense Puts A World Of (Antitrust) Hurt On 3M

Commentators who have declared inequitable conduct dead and buried should study TransWeb, LLC v. 3M Innovative Properties Co., App. No. 2014-1646 (Fed. Cir., Feb. 10 2016). {A copy can be found at the end of this post.] The decision demonstrates … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Labeling GMO’s — Too Late and Too Much

Commentators arguing that genetically-modified plants (and animals) or “GMO’s” have been prepared by conventional plant breeding, fail to address the central issue driving the debate about the safety of genetically-engineered crops intended for human consumption.  The issue is not whether … Continue reading

Posted in Miscellaneous, Uncategorized | Tagged , , , , , , , , | Leave a comment